Association between pre-operative Cefazolin dose and surgical site infection in obese patients

Surgical Infections

Volumn 18, Issue 4, 2017, Pages 485-490

  Peppard, William J ^a,b   Eberle, David G ^a   Kugler, Nathan W ^b   Mabrey, Danielle M ^a   Weigelt, John A ^b  

^a Froedtert and the Medical   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

cefazolin; pharmacokinetics; surgical site infection

Indexed keywords

CEFAZOLIN; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC PROPHYLAXIS; COMPARATIVE EFFECTIVENESS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEMALE; FOLLOW UP; HUMAN; INFECTION RATE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OBESITY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; SURGICAL INFECTION; AGED; COMPLICATION; MIDDLE AGED; RISK FACTOR; SURGICAL WOUND INFECTION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; CEFAZOLIN; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; RETROSPECTIVE STUDIES; RISK FACTORS; SURGICAL WOUND INFECTION;

EID: 85019715220     PISSN: 10962964     EISSN: 15578674     Source Type: Journal    
DOI: 10.1089/sur.2016.182     Document Type: Conference Paper

References (15)

1. Squires DA. Explaining High health care spending in the united states: An international comparison of supply, utilization, prices, and quality. The Commonwealth Fund 2012;10:1-14
2. Silber JH, Rosenbaum PR, Kelz RR, et al. Medical and financial risks associated with surgery in the elderly obese. Ann Surg 2012;256:79-86
3. Huttunen R, Syrjanen J. Obesity and the risk and outcome of infection. Int J Obes (Lond) 2013;37:333-340
4. Thelwall S, Harrington P, Sheridan E, Lamagni T. Impact of obesity on the risk of wound infection following surgery: Results from a nationwide prospective multicentre cohort study in England. Clin Microbiol Infect 2015;21:1008 e1-8
5. van Kralingen S, Taks M, Diepstraten J, et al. Pharmacokinetics and protein binding of cefazolin in morbidly obese patients. Eur J Clin Pharmacol 2011;67:985-992
6. Ho VP, Nicolau DP, Dakin GF, et al. Cefazolin dosing for surgical prophylaxis in morbidly obese patients. Surg Infect 2012;13:33-37
7. Brill MJ, Houwink AP, Schmidt S, et al. Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. J Antimicrob Chemother 2014;69:715-723
8. Pevzner L, Swank M, Krepel C, et al. Effects of maternal obesity on tissue concentrations of prophylactic cefazolin during cesarean delivery. Obstet Gynecol 2011;117:877-882
9. Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 2013;70:195-283
10. Edmiston CE, Krepel C, Kelly H, et al. Perioperative antibiotic prophylaxis in the gastric bypass patient: Do we achieve therapeutic levels? Surgery 2004;136:738-747
11. Swank ML, Wing DA, Nicolau DP, McNulty JA. Increased 3-gram cefazolin dosing for cesarean delivery prophylaxis in obese women. Am J Obstet Gynecol 2015;213:415 e1-8
12. Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery 1962;51:224-232
13. Pories WJ, van Rij AM, Burlingham BT, et al. Prophylactic cefazolin in gastric bypass surgery. Surgery 1981;90:426-432
14. Forse RA, Karam B, MacLean LD, Christou NV. Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery 1989;106:750-756
15. Waltrip T, Lewis R, Young V, et al. A pilot study to determine the feasibility of continuous cefazolin infusion. Surg Infect 2002;3:5-9